The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia

被引：0
|
作者：
Shizuka Sato
Eiko Yamamoto
Kaoru Niimi
Kazuhiko Ino
Kimihiro Nishino
Shiro Suzuki
Tomomi Kotani
Hiroaki Kajiyama
Fumitaka Kikkawa
机构：
[1] Nagoya University Graduate School of Medicine,Department of Obstetrics and Gynecology
[2] Nagoya University Graduate School of Medicine,Department of Healthcare Administration
[3] Wakayama Medical University,Department of Obstetrics and Gynecology
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Actinomycin D; Choriocarcinoma; Etoposide; High-risk gestational trophoblastic neoplasia; Methotrexate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：203 / 209
页数：6
相关论文
共 50 条
  • [1] The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia
    Sato, Shizuka
    Yamamoto, Eiko
    Niimi, Kaoru
    Ino, Kazuhiko
    Nishino, Kimihiro
    Suzuki, Shiro
    Kotani, Tomomi
    Kajiyama, Hiroaki
    Kikkawa, Fumitaka
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (01) : 203 - 209
  • [2] Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy
    Escobar, PF
    Lurain, JR
    Singh, DK
    Bozorgi, K
    Fishman, DA
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 91 (03) : 552 - 557
  • [3] Management of High-Risk Gestational Trophoblastic Neoplasia with Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, Vincristine Chemotherapy
    Cyriac, Sanju
    Rajendranath, Rejiv
    Sridevi, Veluswami
    Sagar, Tenali G.
    [J]. JOURNAL OF REPRODUCTIVE MEDICINE, 2011, 56 (5-6) : 219 - 223
  • [4] Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors
    Matsui, H
    Suzuka, K
    Iitsuka, Y
    Seki, K
    Sekiya, S
    [J]. GYNECOLOGIC ONCOLOGY, 2000, 78 (01) : 28 - 31
  • [5] High-Risk Metastatic Gestational Trophoblastic Neoplasia Primary Management with EMA-CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Chemotherapy
    Cagayan, Ma. Stephanie Fay S.
    [J]. JOURNAL OF REPRODUCTIVE MEDICINE, 2012, 57 (5-6) : 231 - 236
  • [6] Efficacy and safety of the APE (actinomycin D, cisplatin, etoposide) regimen for the management of high-risk gestational trophoblastic neoplasia.
    Lhomme, Catherine
    Even, Caroline
    Duvillard, Pierre
    Pautier, Patricia
    Floquet, Anne
    Kerbrat, Pierre
    Troalen, Frederic
    Rey, Annie
    Balleyguier, Corinne
    Morice, Philippe
    Fizazi, Karim
    Droz, Jean Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia
    Baptista, Angela M.
    Belfort, Paulo
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2012, 119 (01) : 35 - 38
  • [8] Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia
    Turan, T
    Karacay, O
    Tulunay, G
    Boran, N
    Koc, S
    Bozok, S
    Kose, MF
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (03) : 1432 - 1438
  • [9] Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia
    Even, C.
    Pautier, P.
    Duvillard, P.
    Floquet, A.
    Kerbrat, P.
    Troalen, F.
    Rey, A.
    Balleyguier, C.
    Tazi, Y.
    Leary, A.
    Augereau, P.
    Morice, P.
    Droz, J. -P.
    Fizazi, K.
    Lhomme, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) : 2082 - 2089
  • [10] TREATMENT OF HIGH-RISK GESTATIONAL TROPHOBLASTIC DISEASE WITH METHOTREXATE, ACTINOMYCIN-D, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY
    LURAIN, JR
    BREWER, JI
    [J]. OBSTETRICS AND GYNECOLOGY, 1985, 65 (06): : 830 - 836
12345